# US Necrotizing Fasciitis Market

> US Necrotizing Fasciitis Market Research Report By Type (Type I, Type Ii, Type Iii) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.06%
- **2024:** $ 58.31 Million
- **2025:** $ 62.43 Million
- **2035:** $ 123.45 Million
- **Key Players:** Johnson & Johnson (US), Merck & Co (US), Pfizer Inc (US), Baxter International (US), GSK (GB), AstraZeneca (GB), Novartis AG (CH), Sanofi (FR), Boehringer Ingelheim (DE)

**Report ID:** MRFR/Pharma/18439-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-necrotizing-fasciitis-market-19986

---

## Market Summary

## **US Necrotizing Fasciitis Market Overview**

As per MRFR analysis, the US Necrotizing Fasciitis Market Size was estimated at 69.08 (USD Million) in 2023. The US Necrotizing Fasciitis Market Industry is expected to grow from 81.27(USD Million) in 2024 to 156.85 (USD Million) by 2035. The US Necrotizing Fasciitis Market CAGR (growth rate) is expected to be around 6.16% during the forecast period (2025 - 2035).

### **Key US Necrotizing Fasciitis Market Trends Highlighted**

The US necrotizing fasciitis market is currently driven by an increase in the incidence of diabetes and obesity, which are known risk factors for this severe infection. The rising awareness of necrotizing fasciitis, propelled by media coverage and patient advocacy, is prompting more individuals to seek timely medical attention. Moreover, advancements in surgical techniques and the availability of innovative antibiotics are enhancing treatment options, contributing to better patient outcomes.

Furthermore, the push towards improving hospital infection control practices and antibiotic stewardship is vital, as it aims to reduce the spread of infections contributing to necrotizing fasciitis cases. Opportunities in the US market include advancements in telemedicine, which can help facilitate early diagnosis and reduce delays in treatment. There is considerable potential for developing new therapeutics that target the bacterial strains linked to necrotizing fasciitis, as well as creating education programs that emphasize the importance of recognizing early signs of infection.

Additionally, collaborations between pharmaceutical companies and healthcare providers may lead to comprehensive treatment protocols, which can significantly improve care delivery. In recent times, there has been a noticeable increase in research aimed at understanding the microbiological landscape of necrotizing fasciitis, with a focus on its epidemiology in the US. Healthcare institutions are starting to prioritize the implementation of multidisciplinary teams to effectively handle these complex cases.

The emphasis on patient-centered care is also changing how treatments are approached, leading to a more coordinated effort among surgeons, infectious disease specialists, and rehabilitation experts. These trends indicate a growing recognition of the need for comprehensive strategies to combat this life-threatening condition effectively.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Necrotizing Fasciitis Market Drivers**

### **Increasing Incidence of Chronic Diseases**

The US [Necrotizing Fasciitis Market](../../../reports/necrotizing-fasciitis-market-5450) Industry is expected to see significant growth due to the rising incidence of chronic diseases, particularly diabetes, which is a noted predisposing factor for necrotizing fasciitis. According to the Centers for Disease Control and Prevention (CDC), as of 2022, approximately 34.2 million people in the United States, or 10.5% of the population, have diabetes. This chronic condition increases the risk of infections and complications, thereby contributing to the demand for specialized treatments and medications aimed at combating necrotizing fasciitis.

The increasing number of diabetic patients necessitates enhanced medical interventions, promoting further development within the US Necrotizing Fasciitis Market Industry. Major healthcare organizations, such as the American Diabetes Association, are actively involved in campaigns and initiatives aimed at better management of diabetes, thereby indirectly supporting market growth in this domain.

### **Advancements in Medical Technology**

Innovation in medical technology plays a crucial role in advancing treatment options for necrotizing fasciitis, significantly driving the US Necrotizing Fasciitis Market Industry. The introduction of novel surgical techniques, such as minimally invasive procedures and improved wound care management systems, are crucial. According to a report from the Food and Drug Administration (FDA), advancements in surgical devices and wound healing products have improved patient outcomes and reduced recovery times.

Furthermore, the increase in Research and Development (R&D) investment from notable medical technology companies has led to the introduction of cutting-edge products designed specifically for aggressive and complex infections. This progress enhances treatment capabilities, which is vital for healthcare providers addressing necrotizing fasciitis in the US.

### **Growing Awareness and Education on Necrotizing Fasciitis**

Public awareness and education initiatives aimed at necrotizing fasciitis are increasing, which significantly influences the US Necrotizing Fasciitis Market Industry. Organizations such as the National Institute of Health (NIH) have been proactive in launching awareness campaigns that educate the public about the signs and symptoms of this serious condition. This increased awareness can lead to earlier diagnosis and treatment, reducing mortality rates and improving overall patient outcomes.

As more individuals recognize the severity of necrotizing fasciitis, there is a growing demand for medical consultation and intervention, fueling the market growth further. The heightened educational efforts also encourage healthcare professionals to stay updated with the latest treatment protocols, significantly impacting the overall market dynamics.

## **US Necrotizing Fasciitis Market Segment Insights**

### **Necrotizing Fasciitis Market Type Insights**

The US Necrotizing Fasciitis Market represents an area of significant concern and study within the healthcare sector, with a particular emphasis on its classification by Type. The primary categoriesType I, Type II, and Type IIIare based on the bacterial profiles associated with the condition, each presenting unique characteristics and challenges for diagnosis and treatment. Type I is generally a polymicrobial infection that includes a mixture of aerobic and anaerobic bacteria, which complicates its management due to the diversity of pathogens involved.

This complexity necessitates a comprehensive treatment approach, often involving a combination of surgical intervention and aggressive antibiotic therapy. Type II, characterized primarily by the virulent Streptococcus pyogenes along with other pathogens, is notable for its rapid progression and severity, making early recognition and treatment critical to patient outcomes. This type is often associated with trauma or breaks in the skin, which raises awareness regarding preventive measures and the importance of emergency healthcare readiness.

Type III is mainly linked to infections caused by vibrio species and is particularly significant in coastal regions where exposure to seawater is prevalent. While it may represent a smaller proportion of cases, Type III necessitates specific clinical vigilance due to its potentially high mortality rate and the need for targeted therapeutic strategies. Overall, these distinctions among Types not only shape the clinical management of necrotizing fasciitis but also influence the US Necrotizing Fasciitis Market segmentation strategy.

Understanding these classifications aids in the development of tailored treatment programs and informs healthcare policy regarding resource allocation for this critical condition. As the understanding of these types deepens, it opens up opportunities for innovations in diagnostics and therapeutics that can further improve clinical outcomes and drive market growth within this segment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Necrotizing Fasciitis Market Key Players and Competitive Insights**

The competitive insights of the US Necrotizing Fasciitis Market reflect a landscape characterized by the urgent need for effective treatment options and the presence of established pharmaceutical companies that drive innovation and accessibility. Necrotizing fasciitis is a life-threatening soft tissue infection requiring prompt medical intervention, leading to increased attention on research and development within the sector. Numerous key players compete by focusing on novel therapeutics, clinical advancements, and improved patient outcomes.

With a heightened emphasis on partnerships, collaborations, and strategic alliances, the competitive dynamics within this market are shaped by the necessity to offer solutions that address the complexities associated with this severe condition. As healthcare providers continually seek better therapeutic options, companies are striving to meet these needs while navigating regulatory challenges and market demands.

Merck and Co holds a noteworthy position in the US Necrotizing Fasciitis Market, recognized for its innovative approach towards combating infectious diseases. The company has established a strong reputation due to its commitment to research and development, which fosters the creation of groundbreaking therapies. Merck's extensive experience in the pharmaceutical field is complemented by a robust pipeline of products that address a wide range of infections, enhancing its market presence.

Additionally, the company benefits from strategic collaborations with healthcare institutions and research organizations, which facilitate trials and enhance product visibility. Merck's focus on developing antibiotics and antifungal agents specifically targeted at bacterial infections further underscores its strengths in addressing the urgent medical need associated with necrotizing fasciitis.

Takeda, another key player in the US Necrotizing Fasciitis Market, emphasizes its commitment to improving health outcomes through innovation and patient-centered solutions. The company’s portfolio includes various treatments directed at serious infections and inflammatory diseases, demonstrating its capabilities in managing complex health issues, including necrotizing fasciitis. Takeda is known for its strength in developing biologics and specialty pharmaceuticals, assets that significantly contribute to its effectiveness in treating severe conditions.

The company actively pursues strategic mergers and acquisitions to bolster its innovation pipeline, enhance its market positioning, and diversify its offerings. This proactive approach allows Takeda to expand its reach and advance the treatment landscape specifically for necrotizing fasciitis, as it aligns itself with the changing needs of the US healthcare market.

### **Key Companies in the US Necrotizing Fasciitis Market Include**

## **US Necrotizing Fasciitis Market Industry Developments**

The US Necrotizing Fasciitis Market has recently seen significant developments, with heightened awareness regarding this severe infection drawing attention from major pharmaceutical companies. Notably, Merck and Co, Pfizer, and Amgen have prioritized Research and Development for novel therapies aimed at addressing this condition. Current affairs indicate a growing focus on antimicrobial resistance, influencing product development strategies for firms like Eli Lilly and Bristol Myers Squibb.

In the realm of mergers and acquisitions, Takeda recently acquired a biotech firm in September 2023, enhancing its portfolio related to infectious diseases, which could impact treatment options for necrotizing fasciitis. Additionally, in July 2022, Johnson and Johnson bolstered its efforts in antibiotic research through a partnership with a research organization, thus supporting innovative solutions for severe infections. Market valuations are trending upwards, reflecting increased investments and a rising patient population necessitating effective treatments.

With projections indicating continued growth in healthcare expenditure, companies such as Roche and AbbVie are likely to play pivotal roles in addressing the clinical needs arising from necrotizing fasciitis in the US market.

## **US Necrotizing Fasciitis Market Segmentation Insights**

### **Necrotizing Fasciitis Market Type Outlook**

## Market Drivers

### Increasing Incidence Rates

The rising incidence rates of necrotizing fasciitis in the US appear to be a significant driver for the necrotizing fasciitis market. Recent data indicates that the annual incidence of this severe infection is approximately 0.4 to 0.8 cases per 100,000 individuals. This increase may be attributed to various factors, including the aging population and the prevalence of diabetes and obesity, which are known risk factors. As more cases are diagnosed, the demand for effective treatment options and healthcare resources is likely to grow, thereby expanding the market. Furthermore, the heightened awareness among healthcare professionals regarding early diagnosis and intervention may contribute to the increasing number of reported cases, further influencing market dynamics.

### Rising Demand for Surgical Interventions

The rising demand for surgical interventions in the treatment of necrotizing fasciitis is a notable driver for the necrotizing fasciitis market. Surgical debridement remains a critical component of managing this life-threatening condition, and as awareness of the disease increases, more patients may seek surgical options. Data suggests that surgical intervention is required in approximately 80% of cases to remove necrotic tissue effectively. This trend indicates a potential increase in surgical procedures, which could lead to a corresponding rise in the market for surgical instruments and postoperative care products. The emphasis on timely surgical intervention may also drive innovations in surgical techniques and technologies, further influencing market dynamics.

### Technological Advancements in Diagnostics

Technological advancements in diagnostic tools are likely to play a crucial role in shaping the necrotizing fasciitis market. Innovations such as rapid molecular testing and advanced imaging techniques enable healthcare providers to diagnose necrotizing fasciitis more accurately and swiftly. For instance, the use of MRI and CT scans can significantly reduce the time to diagnosis, which is critical for improving patient outcomes. As diagnostic technologies continue to evolve, they may lead to earlier detection and treatment, thereby increasing the overall market size. The integration of artificial intelligence in diagnostic processes also holds potential for enhancing accuracy and efficiency, which could further stimulate growth in the necrotizing fasciitis market.

### Enhanced Focus on Infection Control Practices

An enhanced focus on infection control practices within healthcare settings is likely to impact the necrotizing fasciitis market positively. As hospitals and clinics implement stricter infection control protocols, the incidence of hospital-acquired infections may decrease, potentially reducing the cases of necrotizing fasciitis. The Centers for Disease Control and Prevention (CDC) emphasizes the importance of infection prevention strategies, which may lead to improved patient safety and outcomes. This focus on infection control could also drive demand for related products and services, such as antiseptics and sterilization equipment, thereby contributing to the overall growth of the necrotizing fasciitis market.

### Growing Investment in Healthcare Infrastructure

The growing investment in healthcare infrastructure in the US is another driver influencing the necrotizing fasciitis market. Increased funding for hospitals and healthcare facilities enhances the capacity to treat complex infections, including necrotizing fasciitis. According to recent reports, healthcare spending in the US is projected to reach approximately $6 trillion by 2027, which may facilitate the development of specialized units for infectious diseases. This investment is likely to improve access to advanced treatment options and specialized care, thereby positively impacting patient outcomes. As healthcare systems strengthen their capabilities, the necrotizing fasciitis market may experience growth due to improved treatment availability and patient management.

## Future Outlook

The [Necrotizing Fasciitis Market](https://www.marketresearchfuture.com/reports/necrotizing-fasciitis-market-5450) is projected to grow at a 7.06% CAGR from 2025 to 2035, driven by advancements in treatment options and increased awareness.

**New opportunities:**

- Development of telemedicine platforms for remote consultations Investment in rapid diagnostic testing technologies Expansion of specialized surgical centers for advanced care

By 2035, the necrotizing fasciitis market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Type I (Largest) vs. Type II (Fastest-Growing)

The market share distribution among the Type segment values in the US necrotizing fasciitis market reveals that Type I remains the largest contributor, commanding a significant portion of the market. Following closely is Type II, which has shown a remarkable increase in interest and adoption, particularly among clinicians seeking advanced treatment options, thus enhancing its market presence over Type III and others.

Growth trends indicate that Type II is poised for rapid expansion, driven by increasing awareness of necrotizing fasciitis and advancements in medical technologies. The growing incidence of both Type I and Type II cases has prompted further research and development initiatives, fostering a more dynamic environment. Additionally, support from healthcare institutions for better treatment protocols is facilitating this growth, favoring Type II's emerging status.

Type I (Dominant) vs. Type II (Emerging)

Type I is characterized by a polymicrobial infection and accounts for a substantial portion of the total cases within the US necrotizing fasciitis market, benefiting from established treatment protocols and clinician familiarity. Conversely, Type II, primarily a monomicrobial infection caused by Streptococcus, is emerging with potential for growth due to its aggressive nature and increasing recognition among healthcare providers. The urgency for prompt diagnosis and treatment in Type II cases is leading to innovations in therapeutic approaches, making it a focal point for research. The contrast in treatment methodologies for both types further exemplifies their distinct market positioning, where Type I remains dominant and Type II is rapidly carving out its niche.

### By Treatment: Intravenous Antibiotics (Largest) vs. Surgery (Fastest-Growing)

In the treatment segment, intravenous antibiotics currently hold the largest market share, widely used for early intervention in necrotizing fasciitis due to their effectiveness in combating infection. Surgery follows closely behind, evolving into the fastest-growing option as surgical techniques improve and more cases are diagnosed at an earlier stage. Hyperbaric oxygen treatment and various other modalities also contribute to the treatment landscape, albeit with smaller shares.

The growth trends in this segment are driven primarily by the increasing incidence of necrotizing fasciitis cases, heightened awareness of the condition, and advancements in medical technology. Among these treatment options, surgery is rapidly gaining traction as a critical intervention method, propelled by innovations in surgical processes and post-operative care. The expanding interplay of intravenous antibiotics and surgical interventions showcases a holistic approach to managing necrotizing fasciitis, highlighting the need for comprehensive treatment protocols.

Intravenous Antibiotics (Dominant) vs. Surgery (Emerging)

Intravenous antibiotics remain the dominant modality in the treatment segment due to their essential role in combating the severe infections associated with necrotizing fasciitis. Their broad-spectrum efficacy allows for immediate management of the bacterial threat during initial treatment phases. Meanwhile, surgery is emerging as a crucial treatment option, particularly as techniques advance and evidence mounts regarding its efficacy in preventing complications and improving recovery times. The integration of advanced surgical practices, alongside the established use of antibiotics, marks a significant evolution in the treatment landscape and reflects the dynamic interplay of these approaches to effectively tackle necrotizing fasciitis.

### By End Users: Hospitals & Clinics (Largest) vs. Surgical Centers (Fastest-Growing)

In the US necrotizing fasciitis market, hospitals & clinics dominate the end users segment, capturing a significant share due to their established infrastructure and ability to provide comprehensive care. Surgical centers have been gaining traction, particularly as outpatient procedures increase, leading to a shift in patient management for such severe conditions. The distribution among these end users indicates that hospitals & clinics remain the primary destinations for treatment, while surgical centers are gradually taking a larger role in care delivery.  

The growth trends in this segment are influenced by several factors. Increasing awareness of necrotizing fasciitis leads to higher patient inflow in hospitals, while advancements in surgical techniques make surgical centers an appealing option for rapid interventions. The focus on improved recovery times and reduced hospital stays encourages patients and providers to consider surgical centers. Overall, the end users segment is evolving with a clear distinction between the established dominance of hospitals & clinics and the emerging prominence of surgical centers.

Hospitals & Clinics (Dominant) vs. Surgical Centers (Emerging)

Hospitals & clinics represent the dominant force in the US necrotizing fasciitis market, characterized by a comprehensive range of services that support inpatient and outpatient care. Their ability to manage complex cases and provide intensive treatment protocols is critical in addressing severe infections. Conversely, surgical centers are emerging as a viable alternative, focusing on less invasive procedures and quicker recovery times, making them attractive to patients who prefer outpatient solutions. These centers leverage modern surgical technologies, enabling rapid intervention, which is essential in managing conditions like necrotizing fasciitis. The tension between traditional hospital settings and evolving surgical centers highlights a dynamic shift in patient care approaches.

## Competitive Benchmarking

The necrotizing fasciitis market exhibits a complex competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on enhancing patient outcomes. Key players such as Johnson & Johnson (US), Merck & Co (US), and Pfizer Inc (US) are actively shaping the market dynamics through their distinct operational strategies. Johnson & Johnson (US) emphasizes innovation in surgical interventions and wound care products, while Merck & Co (US) focuses on developing advanced antibiotic therapies. Pfizer Inc (US) is leveraging its extensive research capabilities to explore novel treatment modalities, thereby enhancing its competitive positioning. Collectively, these strategies foster a competitive environment that prioritizes patient-centric solutions and technological advancements.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the necrotizing fasciitis market appears moderately fragmented, with several players vying for market share. This fragmentation is indicative of a landscape where innovation and operational efficiency are paramount, allowing key players to exert considerable influence over market trends and consumer preferences.
In October Merck & Co (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel monoclonal antibody targeting necrotizing fasciitis. This collaboration is poised to enhance Merck's portfolio and accelerate the development of targeted therapies, reflecting a strategic shift towards precision medicine. The significance of this partnership lies in its potential to address unmet medical needs and improve treatment outcomes for patients suffering from this severe condition.
In September Pfizer Inc (US) launched a new clinical trial aimed at evaluating the efficacy of its latest antibiotic formulation against necrotizing fasciitis. This initiative underscores Pfizer's commitment to addressing critical gaps in treatment options. The trial's outcomes could potentially reshape treatment protocols and establish Pfizer as a leader in this niche market, thereby enhancing its competitive edge.
In August Johnson & Johnson (US) expanded its product line with the introduction of an innovative wound care solution specifically designed for necrotizing fasciitis patients. This product launch not only diversifies Johnson & Johnson's offerings but also demonstrates its proactive approach to addressing the complexities of wound management. The strategic importance of this launch lies in its alignment with current trends towards personalized and effective treatment solutions.
As of November the competitive trends in the necrotizing fasciitis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances research and development capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift indicates a market poised for transformation, where the emphasis on patient outcomes and advanced therapeutic options will drive future growth.

## Recent News & Developments

The US Necrotizing Fasciitis Market has recently seen significant developments, with heightened awareness regarding this severe infection drawing attention from major pharmaceutical companies. Notably, Merck and Co, Pfizer, and Amgen have prioritized Research and Development for novel therapies aimed at addressing this condition. Current affairs indicate a growing focus on antimicrobial resistance, influencing product development strategies for firms like Eli Lilly and Bristol Myers Squibb.

In the realm of mergers and acquisitions, Takeda recently acquired a biotech firm in September 2023, enhancing its portfolio related to infectious diseases, which could impact treatment options for necrotizing fasciitis. Additionally, in July 2022, Johnson and Johnson bolstered its efforts in antibiotic research through a partnership with a research organization, thus supporting innovative solutions for severe infections. Market valuations are trending upwards, reflecting increased investments and a rising patient population necessitating effective treatments.

With projections indicating continued growth in healthcare expenditure, companies such as Roche and AbbVie are likely to play pivotal roles in addressing the clinical needs arising from necrotizing fasciitis in the US market.

## Report Scope

| MARKET SIZE 2024 | 58.31(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 62.43(USD Million) |
| MARKET SIZE 2035 | 123.45(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.06% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Johnson & Johnson (US), Merck & Co (US), Pfizer Inc (US), Baxter International (US), GSK (GB), AstraZeneca (GB), Novartis AG (CH), Sanofi (FR), Boehringer Ingelheim (DE) |
| Segments Covered | Type, Treatment, End Users |
| Key Market Opportunities | Advancements in rapid diagnostic technologies enhance early detection in the necrotizing fasciitis market. |
| Key Market Dynamics | Rising awareness and advancements in treatment options drive growth in the necrotizing fasciitis market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current market valuation of the US necrotizing fasciitis market?**
A: The market valuation was $58.31 Million in 2024.

**Q: What is the projected market size for the US necrotizing fasciitis market by 2035?**
A: The projected market size is $123.45 Million by 2035.

**Q: What is the expected CAGR for the US necrotizing fasciitis market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.06% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the US necrotizing fasciitis market?**
A: Key players include Johnson & Johnson, Merck & Co, Pfizer Inc, Baxter International, GSK, AstraZeneca, Novartis AG, Sanofi, and Boehringer Ingelheim.

**Q: What are the main treatment segments in the US necrotizing fasciitis market?**
A: Main treatment segments include intravenous antibiotics, surgery, hyperbaric oxygen treatment, and others.

**Q: What was the valuation of the intravenous antibiotics segment in 2024?**
A: The valuation of the intravenous antibiotics segment was between $20.0 Million and $40.0 Million in 2024.

**Q: How does the Type I segment perform in the US necrotizing fasciitis market?**
A: The Type I segment had a valuation range of $20.0 Million to $40.0 Million in 2024.

**Q: What is the expected growth for surgical centers as end users in the US necrotizing fasciitis market?**
A: Surgical centers are expected to have a valuation range of $15.0 Million to $30.0 Million in 2024.

**Q: What is the projected growth for the hyperbaric oxygen treatment segment by 2035?**
A: The hyperbaric oxygen treatment segment is projected to grow to a valuation range of $5.0 Million to $15.0 Million by 2035.

**Q: What are the anticipated trends for hospitals and clinics as end users in the US necrotizing fasciitis market?**
A: Hospitals and clinics had a valuation range of $30.0 Million to $62.0 Million in 2024, indicating strong demand.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-necrotizing-fasciitis-market-19986*